1-4 of 4
Najla Al Ali
Close
Sort by
Journal Articles

Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1 -mutated AML

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda Deutsch, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew Kuykendall, Eric Padron, Alison Walker, Gail Roboz, Pinkal Desai, David Sallman, Kendra Sweet, Rami Komrokji, Jeffrey Lancet
Journal: Blood Advances
Blood Adv (2024) 8 (5): 1075–1083.
https://doi.org/10.1182/bloodadvances.2023011173
Published: 2024
Journal Articles

Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival

Naseema Gangat, Andrew Kuykendall, Najla Al Ali, Swati Goel, Maymona Abdelmagid, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek Mangaonkar, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Rami Komrokji, Ayalew Tefferi
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2694–2698.
https://doi.org/10.1182/bloodadvances.2022009611
Published: 2023
Journal Articles

U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes

Rami Komrokji, Luis E. Aguirre, Najla Al Ali, Mohamad Hussaini, David Sallman, Dana Rollison, Eric Padron
Journal: Blood Advances
Blood Adv (2023) 7 (1): 1–8.
https://doi.org/10.1182/bloodadvances.2022007504
Published: 2023
Journal Articles

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Clinical Trials & Observations
Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Eric Padron, Alan F. List, David A. Sallman
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1017–1028.
https://doi.org/10.1182/bloodadvances.2020003508
Published: 2021
Includes: Supplemental data